+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review

  • ID: 4267304
  • SWOT Analysis
  • June 2019
  • Region: Global
  • 50 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Accelerate Diagnostics I
  • ARUP Laboratories
  • AutoGenomics Inc
  • bioMerieux SA
  • Curetis NV
  • Eurofins Genomics GmbH
  • MORE
OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. OpGen’s develops products that include QuickFISH, and PNA FISH products, Acuitas products, and Acuitas Lighthouse informatics. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc Key Recent Developments

May 14,2019: OpGen reports first quarter 2019 financial results and provides business update
Mar 25,2019: OpGen and Merck’s ILÚM Health Solutions to host event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
Feb 25,2019: OpGen names R. Don Elsey as board director
Nov 13,2018: OpGen reports third quarter 2018 financial results and provides business update
Oct 15,2018: OpGen provides business and preliminary financial update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Accelerate Diagnostics I
  • ARUP Laboratories
  • AutoGenomics Inc
  • bioMerieux SA
  • Curetis NV
  • Eurofins Genomics GmbH
  • MORE
Section 1 - About the Company
OpGen Inc - Key Facts
OpGen Inc - Key Employees
OpGen Inc - Key Employee Biographies
OpGen Inc - Major Products and Services
OpGen Inc - History
OpGen Inc - Company Statement
OpGen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
OpGen Inc - Business Description
Product Category: Collaboration Revenue
Overview
Performance
Product Category: Laboratory Services
Overview
Performance
Product Category: Product Sales
Overview
Performance
R&D Overview
OpGen Inc - Corporate Strategy
OpGen Inc - SWOT Analysis
SWOT Analysis - Overview
OpGen Inc - Strengths
OpGen Inc - Weaknesses
OpGen Inc - Opportunities
OpGen Inc - Threats
OpGen Inc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
OpGen Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments
May 14, 2019: OpGen reports first quarter 2019 financial results and provides business update
Mar 25, 2019: OpGen and Merck’s ILÚM Health Solutions to host event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship
Feb 25, 2019: OpGen names R. Don Elsey as board director
Nov 13, 2018: OpGen reports third quarter 2018 financial results and provides business update
Oct 15, 2018: OpGen provides business and preliminary financial update
Aug 02, 2018: Opgen announces second quarter 2018 financial results
May 08, 2018: OpGen Announces First Quarter 2018 Financial Results
Apr 19, 2018: OpGen Completes Rapid Testing Clinical Trial In Colombia And Expands International Operations
Mar 15, 2018: OpGen Announces Fourth Quarter and Full Year 2017 Financial Results
Mar 13, 2018: OpGen Announces Collaborator in Verification Study for Acuitas Test

Section 6 – Appendix
Methodology
Ratio Definitions
About the Publisher
Contact Us
Disclaimer

List of Tables
OpGen Inc, Key Facts
OpGen Inc, Key Employees
OpGen Inc, Key Employee Biographies
OpGen Inc, Major Products and Services
OpGen Inc, History
OpGen Inc, Subsidiaries
OpGen Inc, Key Competitors
OpGen Inc, Ratios based on current share price
OpGen Inc, Annual Ratios
OpGen Inc, Annual Ratios (Cont...1)
OpGen Inc, Interim Ratios
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
OpGen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
OpGen Inc, Performance Chart (2014 - 2018)
OpGen Inc, Ratio Charts
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • T2 Biosystems Inc
  • AutoGenomics Inc
  • Quest Diagnostics Inc
  • Eurofins Genomics GmbH
  • Curetis NV
  • GenMark Diagnostics Inc
  • Nanosphere Inc
  • bioMerieux SA
  • Laboratory Corp of America Holdings
  • ARUP Laboratories
  • Accelerate Diagnostics I
Note: Product cover images may vary from those shown
Adroll
adroll